Cogan's syndrome — a rare inflammatory disorder primarily involving the eyes and the inner ear — is exceptionally uncommon in children and adolescents. Managing it in this age group presents particular challenges, as evidence is drawn from a very small number of documented pediatric cases.
Patient age under 18 years with a diagnosis of Cogan's syndrome. The condition has been very rarely described in children, with approximately fifty reported cases in the literature worldwide. The auditory system and the eyes are the primary systems affected.
Biologic therapy has been documented in this pediatric setting. Infliximab is among the agents reported in children — the complete treatment strategy, clinical decision points, and management framework are available in the full structured protocol.
DOI: 10.1016/j.revmed.2024.09.007
Cogan's syndrome is a complex condition primarily affecting the auditory system and the eyes and has been very rarely described in children, with around fifty reported cases.
Infliximab is the only reported biologic agent in children with good tolerability, but the therapeutic approach is generally guided by the experience of adult physicians.
View source ↗